CG
ACET icon

Cutler Group’s Adicet Bio ACET Stock Holding History

Cutler Group’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3
Closed – – 4591
2020
Q2 		$0 Hold
3
– – ﹤0.01% 4287
2020
Q1 		$0 Buy
+3
New +$445 ﹤0.01% 3924

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Cutler Group's ACET Position: Q3 2020 in Review

Cutler Group sold out of Adicet Bio (ACET) in Q3 2020, closing a stake of 3 shares.

Cutler Group first reported a position in ACET in Q1 2020 and held it in 2 quarters. The position peaked at $0 in Q2 2020. 32 funds tracked by Wall St. Rank hold ACET as of Q3 2020.

  • Cutler Group reported no remaining Adicet Bio position as of Q3 2020 after selling out during the quarter.
  • Cutler Group sold 3 Adicet Bio shares in Q3 2020.
  • Cutler Group first reported a position in Adicet Bio in Q1 2020 and held it in 2 quarters.
  • Cutler Group's Adicet Bio position peaked at $0 in Q2 2020.
  • 32 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2020.

Based on Cutler Group's 13F filing for Q3 2020, filed 27 Oct 2020.